Syndivia has acquired an exclusive license from SATT Conectus for DARx technology, which enables the generation of 1-to-1 conjugates (DAR1) using readily available protein substrates, such as therapeutic antibodies. The antibody-drug and antibody-oligonucleotide conjugates with a degree of conjugation of 1 (DAR1), produced through DARx, have demonstrated improved therapeutic indices owing to enhanced pharmacokinetics and pharmacodynamics (PK/PD) parameters.
For more information, please refer to: https://www.prnewswire.com/news-releases/syndivia-in-licenses-darx-technology-for-1-to-1-linkage-of-antibodies-and-payloads-for-preparation-of-new-classes-of-biologics-300993733.html